AR073760A1 - HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME - Google Patents

HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME

Info

Publication number
AR073760A1
AR073760A1 ARP090103820A ARP090103820A AR073760A1 AR 073760 A1 AR073760 A1 AR 073760A1 AR P090103820 A ARP090103820 A AR P090103820A AR P090103820 A ARP090103820 A AR P090103820A AR 073760 A1 AR073760 A1 AR 073760A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
heterocyclyl
group
nitrogen
Prior art date
Application number
ARP090103820A
Other languages
Spanish (es)
Inventor
Helen Maureen Mcguire
Suzanne Stokes
David Charles Mckinney
Ann Boriack-Sjodin
Daniel Robert Carcanague
Daemian David Dussault
Holia Hatoum-Mokdad
Kenneth Gregory Hull
Georgine Ioannidis
John Irvin Manchester
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR073760A1 publication Critical patent/AR073760A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También se describen procesos para su preparacion, composiciones farmacéuticas que los contienen, su uso como medicamentos y su uso en el tratamiento de infecciones bacterianas. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1): o una sal farmacéuticamente aceptable del mismo, en donde: X es CH o N; R1 es hidrogeno, un alquilo C1-6, alquenilo C2-6, alquinilo C2-6, carbociclilo C3-14 o un heterociclilo, en donde R1 puede estar opcionalmente sustituido sobre carbono por uno o más R6; y en donde si dicho heterociclilo contiene un = N-. o un resto -S- ese nitrogeno puede estar opcionalmente sustituido por un grupo oxo y ese azufre puede estar opcionalmente sustituido por uno o dos grupos oxo; y en donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R7; siempre que R1 no sea un fenilo sustituido o insustituido; R2 es hidrogeno o un alquilo C1-6; o R1 y R2, junto con el nitrogeno al que están unidos, forman un heterociclilo, en donde dicho heterociclilo puede estar opcionalmente sustituido sobre carbono por uno o más R8; en donde si dicho heterociclilo contiene un = N- o un resto -S- ese nitrogeno puede estar opcionalmente sustituido por un grupo oxo y ese azufre puede estar opcionalmente sustituido por uno o dos grupos oxo; y en donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R9; R3 es un arilo C6-14 o un heteroarilo; en donde R3 puede estar opcionalmente sustituido sobre carbono por uno o más R14; y en donde si dicho heteroarilo contiene un = N- o un resto -S- ese nitrogeno puede estar opcionalmente sustituido por un grupo oxo y ese azufre puede estar opcionalmente sustituido por uno o dos grupos oxo; y en donde si dicho heteroarilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R15; siempre que R3 no sea un fenilo insustituido o un tiofenilo insustituido; R4 en cada caso, se selecciona independientemente del grupo que consiste en halo, ciano, nitro, hidroxi, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, carbamoilo, N-alquil C1-6carbamoilo, N-alcoxi C1-6carbamoilo, N,N-(alquil C1-6)2carbamoilo, N-(SO2R')carbamoilo, N-alquilo C1-6, alquilo C1-6-S(O)a-, R17R18N-S(O)a-, carbociclilo C3-14 y heterociclilo; o dos R4 tomados junto con los átomos de carbono a los que están unidos forman un carbociclilo C3-14 o un heterociclilo, en donde cada R4 puede estar opcionalmente sustituido sobre carbono por uno o más R16 donde si cualquiera de los heterociclilos contiene un grupo -NH- ese nitrogeno puede estar opcionalmente sustituido con un grupo que se selecciona de R26, siempre que el anillo B junto con -(R4)n no sea 3,4,5-trimetoxifenilo; n es un numero entero de 1 a 5; a es 0, 1 o 2; R6, R8 y R14, en cada caso, se seleccionan cada uno independientemente del grupo que consiste en hidroxi, halo, ciano, nitro, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, mercapto, alcoxi C1-6, alquilo C1-6S(O)a en donde a es 0 a 2; -C(=N-OH)NH2, C(O)NHNH2, fenoxi, carboxi, oxo, amino, N-alquil C1-6amino, N,N-(alquil C1-6)2amino, alcoxi C1-6carbonilo, alcanoilo C1-6, alcanoilC1-6oxi, alcanoilC1-6amino, alcoxiC1-6carbonilamino, carbamoilo, N-alquil C1-6carbamoilo, N-alcoxi C1-6carbamoilo, N,N-(alquil C1-6)2carbamoilo, N-alquilo C1-6-N-alcoxicarbamoilo, N-(SO2R')carbamoilo, N-alquilo C1-6-N-(SO2R')carbamoilo, alquilC1-6sulfonilamino, sulfamoilo, N-alquilC1-6sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, sulfamoilamino, N-alquil C1-6sulfamoilamino, N,N-(alquil C1-692sulfamoilamino, carbociclilo C3-14-L- y heterociclilo-L-; o dos R14 tomados junto con los átomos de carbono a los que están unidos forman un carbociclilo C3-14 o un heterociclilo; en donde R6, R8 y R14 pueden estar independientemente opcionalmente sustituidos sobre carbono por uno o más R10; y en donde si dicho heterociclilo contiene un = N- o un resto -S- ese nitrogeno puede estar opcionalmente sustituido por un grupo oxo y ese azufre puede estar opcionalmente sustituido por uno o dos grupos oxo; y en donde si cualquiera de dichos heterociclilos contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R11; R' y Rö, en cada caso, se seleccionan independientemente del grupo que consiste en alquilo C1-4, arilo C6-14 y heterociclilo, en donde R' y Rö pueden estar opcionalmente sustituidos sobre carbono por uno o más R22 y en donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R23; R7, R9, R15 y R23, en cada caso, se seleccionan cada uno independientemente del grupo que consiste en alquilo C1-6, alcoxiC1-6carbonilo, alcanoilo C1-6, carbamoilo, N-alquilC1-6carbamoilo, N,N-(alquil C1-6)2carbamoilo, carbociclilo C3-14-C(O)-, heterociclilo-C(O)-, (alquil C1-6)3sililo, alquilo C1-6S(O)a en donde a es 0 a 2, en donde R7, R9 y R15 pueden estar independientemente opcionalmente sustituidos sobre carbono por uno o más R12; y en donde si dicho heterociclilo contiene un = N- o un resto -S- ese nitrogeno puede estar opcionalmente sustituido por un grupo oxo y ese azufre puede estar opcionalmente sustituido por uno o dos grupos oxo; y en donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R13; L, en cada caso, se selecciona independientemente de un enlace directo, -O-, -N(R25)-, -C(O)-, -N(R25)C(O)-, -C(O)N(R25)-, -S(O)s-, -SO2N(R25)- o -N(R25)SO2-; en donde R25, en cada caso, se selecciona independientemente de hidrogeno o alquilo C1-6 y s es 0, 1 o 2; R10 y R12, en cada caso, se seleccionan independientemente del grupo que consiste en alquilo C1-6, fenilo, halo, ciano, nitro, oxo, carboxi, hidroxi, alcoxi C1-6, alcoxi C1-6carbonilo, amino, N-alquil C1-6amino, N,N-(alquil C1-6)2amino, alcanoilC1-6amino, alquilo C1-6SO2NH-carbamoilo, N-alquil C1-6carbamoilo, N,N-(alquil C1-6)carbamoilo, N-alquil C1-6oxicarbamoilo, alquilo C1-6S(O)a, donde a es 0 a 2, y heterociclilo, donde dicho R10 y R12 están independientemente opcionalmente sustituidos sobre carbono por uno o más alquilo C1-6 y en donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido por un grupo que se selecciona de R13', R11, R13 , R13' y R26, en cada caso, se seleccionan cada uno independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6carbonilo, alcanoilo C1-6, cicloalcanoilo C3-6, carbamoilo, alcanoil C1-6oxi, alquilo C1-6S(O)a, S(O)aarilo en donde a es 0 a 2, carboxi, sulfamoilo y urea en donde dicho R11, R13, R13' y R26 están opcionalmente sustituidos sobre carbono por uno o más amino, alquilo C1-6, alcoxi C1-6 o heterociclilo; R16, en cada caso, es independientemente, un halo, hidroxi, un alquilo C1-6, o un alcoxi C1-6; R17 y R18, en cada caso, son independientemente hidrogeno o un alquilo C1-6; o R17 y R18, junto con el nitrogeno al que están unidos forman un heterociclilo; R22, en cada caso, se selecciona independientemente del grupo que consiste en halo, alquilo C1-6, S(O)aRö en donde a es 0 a 2, alcanoilo C1-6, alcanoil C1-6amino y heterociclilo en donde R22 puede estar opcionalmente sustituido sobre carbono por uno o más R24; R24 se selecciona de halo, alcanoil C1-6amino y heterociclilo; siempre que -NR1R2 no sea -NHCH3 ni -N(CH3)2.Processes for its preparation, pharmaceutical compositions containing them, their use as medicines and their use in the treatment of bacterial infections are also described. Claim 1: A compound characterized in that it is of formula (1): or a pharmaceutically acceptable salt thereof, wherein: X is CH or N; R1 is hydrogen, a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-14 carbocyclyl or a heterocyclyl, wherein R1 may be optionally substituted on carbon by one or more R6; and where if said heterocyclyl contains a = N-. or an -S- moiety that nitrogen may be optionally substituted by an oxo group and that sulfur may be optionally substituted by one or two oxo groups; and wherein if said heterocyclyl contains a -NH- moiety that nitrogen may be optionally substituted by a group selected from R7; provided that R1 is not a substituted or unsubstituted phenyl; R2 is hydrogen or a C1-6 alkyl; or R1 and R2, together with the nitrogen to which they are attached, form a heterocyclyl, wherein said heterocyclyl may be optionally substituted on carbon by one or more R8; wherein if said heterocyclyl contains an = N- or an -S- moiety that nitrogen may be optionally substituted by an oxo group and that sulfur may be optionally substituted by one or two oxo groups; and wherein if said heterocyclyl contains a -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; R3 is a C6-14 aryl or a heteroaryl; wherein R3 may be optionally substituted on carbon by one or more R14; and wherein if said heteroaryl contains an = N- or an -S- moiety that nitrogen may be optionally substituted by an oxo group and that sulfur may be optionally substituted by one or two oxo groups; and wherein if said heteroaryl contains a -NH- moiety that nitrogen may be optionally substituted by a group selected from R15; provided that R3 is not an unsubstituted phenyl or an unsubstituted thiophenyl; R4 in each case, is independently selected from the group consisting of halo, cyano, nitro, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkanoyl, carbamoyl, N-C1-6carbamoyl alkyl, N-C1- alkoxy 6carbamoyl, N, N- (C1-6 alkyl) 2carbamoyl, N- (SO2R ') carbamoyl, N-C1-6 alkyl, C1-6-S (O) a-, R17R18N-S (O) a-, C3-14 carbocyclyl and heterocyclyl; or two R4 taken together with the carbon atoms to which they are attached form a C3-14 carbocyclyl or a heterocyclyl, wherein each R4 can be optionally substituted on carbon by one or more R16 where if any of the heterocyclyls contains a group - NH- that nitrogen may be optionally substituted with a group selected from R26, provided that ring B together with - (R4) n is not 3,4,5-trimethoxyphenyl; n is an integer from 1 to 5; a is 0, 1 or 2; R6, R8 and R14, in each case, are each independently selected from the group consisting of hydroxy, halo, cyano, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, mercapto, C1-6 alkoxy, C1-6S (O) alkyl a wherein a is 0 to 2; -C (= N-OH) NH2, C (O) NHNH2, phenoxy, carboxy, oxo, amino, N-C1-6 alkyl, N, N- (C1-6 alkyl) 2amino, C1-6 alkoxycarbonyl, C1 alkanoyl -6, C 1-6 alkanoyl, C 1-6 alkanoyl, C 1-6 alkoxycarbonylamino, carbamoyl, N-C 1-6 alkylcarbamoyl, N-C 1-6 alkoxycarbamoyl, N, N- (C 1-6 alkyl) 2-carbamoyl, N-C 1-6 alkyl N-alkoxycarbamoyl, N- (SO2R ') carbamoyl, N-C1-6-N- (SO2R') carbamoyl, C 1-6 alkyl sulfonylamino, sulfamoyl, N-C 1-6 alkyl sulfulfyl, N, N- (C 1-6 alkyl) 2 sulfulfyl , sulfamoylamino, N-C1-6sulfamoylamino, N, N- (C1-692 alkyl sulfamoylamino, C3-14-L- carbocyclyl and heterocyclyl-L-; or two R14 taken together with the carbon atoms to which they are attached form a C3-14 carbocyclyl or a heterocyclyl; wherein R6, R8 and R14 can be independently optionally substituted on carbon by one or more R10; and where if said heterocyclyl contains a = N- or a -S-moiety that nitrogen may optionally be substituted by an oxo group and that sulfur can be optionalm entity substituted by one or two oxo groups; and wherein if any of said heterocyclyls contains a -NH- moiety that nitrogen may be optionally substituted by a group selected from R11; R 'and Rö, in each case, are independently selected from the group consisting of C1-4 alkyl, C6-14 aryl and heterocyclyl, where R' and Rö may be optionally substituted on carbon by one or more R22 and where said heterocyclyl contains a moiety -NH- that nitrogen may be optionally substituted by a group selected from R23; R7, R9, R15 and R23, in each case, are each independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxycarbonyl, C1-6 alkanoyl, carbamoyl, N-C1-6carbamoyl, N, N- (alkyl C1-6) 2carbamoyl, C3-14-C carbocyclyl (O) -, heterocyclyl-C (O) -, (C1-6 alkyl) 3sylyl, C1-6S alkyl (O) a where a is 0 to 2, in where R7, R9 and R15 can be independently optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an = N- or an -S- moiety that nitrogen may be optionally substituted by an oxo group and that sulfur may be optionally substituted by one or two oxo groups; and wherein if said heterocyclyl contains a -NH- moiety that nitrogen may be optionally substituted by a group selected from R13; L, in each case, is independently selected from a direct link, -O-, -N (R25) -, -C (O) -, -N (R25) C (O) -, -C (O) N ( R25) -, -S (O) s-, -SO2N (R25) - or -N (R25) SO2-; wherein R25, in each case, is independently selected from hydrogen or C1-6 alkyl and s is 0, 1 or 2; R10 and R12, in each case, are independently selected from the group consisting of C1-6 alkyl, phenyl, halo, cyano, nitro, oxo, carboxy, hydroxy, C1-6 alkoxy, C1-6 alkoxycarbonyl, amino, N-alkyl C1-6amino, N, N- (C1-6 alkyl) 2amino, C1-6 alkanoyl, C1-6SO2NH-carbamoyl, N-C1-6carbamoyl, N, N- (C1-6 alkyl) carbamoyl, N-C1 alkyl -6oxycarbamoyl, C1-6S alkyl (O) a, where a is 0 to 2, and heterocyclyl, wherein said R10 and R12 are independently optionally substituted on carbon by one or more C1-6 alkyl and wherein said heterocyclyl contains a moiety -NH- that nitrogen may be optionally substituted by a group selected from R13 ', R11, R13, R13' and R26, in each case, each independently selected from the group consisting of C1-6 alkyl, C1- alkoxy 6carbonyl, C1-6 alkanoyl, C3-6 cycloalkanoyl, carbamoyl, C1-6oxy alkanoyl, C1-6S (O) a, S (O) aaryl alkyl wherein a is 0 to 2, carboxy, sulfamoyl and urea wherein said R11 , R13, R1 3 'and R26 are optionally substituted on carbon by one or more amino, C1-6 alkyl, C1-6 alkoxy or heterocyclyl; R16, in each case, is independently a halo, hydroxy, a C1-6 alkyl, or a C1-6 alkoxy; R17 and R18, in each case, are independently hydrogen or a C1-6 alkyl; or R17 and R18, together with the nitrogen to which they are attached form a heterocyclyl; R22, in each case, is independently selected from the group consisting of halo, C1-6 alkyl, S (O) aRö where a is 0 to 2, C1-6 alkanoyl, C1-6 alkanoyl and heterocyclyl where R22 may be optionally substituted on carbon by one or more R24; R24 is selected from halo, C1-6 alkanoyl and heterocyclyl; provided that -NR1R2 is not -NHCH3 or -N (CH3) 2.

ARP090103820A 2008-10-03 2009-10-02 HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME AR073760A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10258308P 2008-10-03 2008-10-03

Publications (1)

Publication Number Publication Date
AR073760A1 true AR073760A1 (en) 2010-12-01

Family

ID=41698441

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103820A AR073760A1 (en) 2008-10-03 2009-10-02 HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME

Country Status (5)

Country Link
US (1) US20100137313A1 (en)
AR (1) AR073760A1 (en)
TW (1) TW201016676A (en)
UY (1) UY32158A (en)
WO (1) WO2010038081A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina Pyrazolopyrimidine compounds for the treatment of cancer
CN103038230B (en) 2010-06-04 2016-05-25 霍夫曼-拉罗奇有限公司 As the aminopyridine derivative of LRRK2 conditioning agent
JP6035238B2 (en) * 2010-07-21 2016-11-30 ライジェル ファーマシューティカルズ， インコーポレイテッド Protein kinase C inhibitor and use thereof
DE102010050558A1 (en) 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-pyrrolo [2,3-b] pyridine
LT3124483T (en) 2010-11-10 2019-09-25 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP3524324A1 (en) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN111499580A (en) 2011-04-22 2020-08-07 西格诺药品有限公司 Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
MX352546B (en) 2011-08-17 2017-11-29 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi.
HUE065564T2 (en) 2011-08-23 2024-06-28 Libertas Bio Inc Pyrimido- pyridazinone compounds and use thereof
JP2014532060A (en) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Pyrrolopyrimidine compounds for the treatment of cancer
NZ627113A (en) * 2012-01-20 2016-07-29 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
EP2626356A1 (en) * 2012-02-08 2013-08-14 Rheinische Friedrich-Wilhelms-Universität Bonn Thiamine analogues and their use as antibiotics
CA2865071C (en) 2012-02-22 2020-06-23 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
CN104302627A (en) * 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 Pyrimidine compounds for the treatment of cancer
ES2704744T3 (en) 2012-06-13 2019-03-19 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
CN102827059A (en) * 2012-09-18 2012-12-19 江苏德峰药业有限公司 Production method for N-tert-butoxycarbonylation-L-ethyl-pyroglutamic acid
CN102827058A (en) * 2012-09-18 2012-12-19 江苏德峰药业有限公司 Production method of N-t-butoxycarbonyl-L-pyroglutamate
CN103709172B (en) * 2012-09-28 2018-02-13 江苏先声药业有限公司 Substituted furan and piperidine derivative and its application
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR20150132345A (en) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac inhibitors
CN109776525B (en) 2013-04-19 2022-01-21 因赛特控股公司 Bicyclic heterocycles as FGFR inhibitors
HUE049733T2 (en) 2013-07-02 2020-10-28 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
CN105592850B (en) 2013-08-06 2019-11-15 H·李·莫菲特癌症中心研究所公司 The inhibitor of ACK1/TNK2 tyrosine kinase
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2015157127A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233809B1 (en) 2014-12-16 2021-04-21 Signal Pharmaceuticals, LLC Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
EP3250557A4 (en) 2015-01-29 2018-06-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10252981B2 (en) 2015-07-24 2019-04-09 Celgene Corporation Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
EP3348554B1 (en) * 2015-09-08 2020-05-06 Sumitomo Chemical Company, Limited Method for producing triazole compound
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
HUE053449T2 (en) 2015-11-05 2021-06-28 Celgene Quanticel Res Inc Compositions comprising an inhibitor of lysine specific demethylase-1 having a pyrimidine ring and its use in the treatment of cancer
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US10710983B2 (en) * 2016-06-27 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
US10562885B2 (en) * 2017-03-06 2020-02-18 Sumitomo Chemical Company, Limited Method for producing triazole compound
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
WO2018183112A1 (en) * 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Heterocyclic compound
JP7525264B2 (en) 2017-04-28 2024-07-30 リベルタス バイオ，インコーポレイティド Formulations, methods, kits, and dosage forms for treating atopic dermatitis and improving the stability of drug substances
WO2018203691A1 (en) * 2017-05-02 2018-11-08 한국화학연구원 Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating tyro 3 related disease comprising same as active ingredient
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
US20210230155A1 (en) * 2018-04-27 2021-07-29 Hetero Labs Limited Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
MX2020011639A (en) 2018-05-04 2021-02-15 Incyte Corp Salts of an fgfr inhibitor.
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
CN110759860B (en) * 2018-07-27 2022-10-14 江苏瑞科医药科技有限公司 Preparation method of 3-methyl formate-4-methoxy-5-cyanopyridine
AR115870A1 (en) 2018-07-31 2021-03-10 Sumitomo Chemical Co METHOD FOR CONTROLLING SOYBEAN ROY FUNGUS THAT HAS RESISTANCE TO SITE INHIBITOR Qₒ
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR102621694B1 (en) * 2022-09-15 2024-01-08 주식회사 스탠다임 Adenosine a2a receptor antagonist and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100658489B1 (en) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. HIV replication inhibiting pyrimidines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU1212501A (en) * 1999-10-21 2001-04-30 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
WO2003032994A2 (en) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel tri-substituted pyrimidines, method for production and use thereof as medicament
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003286711A1 (en) * 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
EP1749827A4 (en) * 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd Anti-tumor agent
RU2405778C2 (en) * 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. Hiv inhibiting 5-heterocyclyl pyrimidines
EP2102199B1 (en) * 2006-12-04 2011-04-27 AstraZeneca AB Antibacterial polycyclic urea compounds
JP2011518219A (en) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Inhibitors of protein kinases

Also Published As

Publication number Publication date
UY32158A (en) 2010-04-30
TW201016676A (en) 2010-05-01
WO2010038081A2 (en) 2010-04-08
US20100137313A1 (en) 2010-06-03
WO2010038081A3 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
AR073760A1 (en) HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME
PE20090648A1 (en) COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
CO2018003565A2 (en) Spiro [3h-indole-3,2'-pyrrolidin] -2 (1h) -one compounds and derivatives as mdm2-p53 inhibitors
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
BR112013007696A2 (en) compound, pharmaceutical composition, uses of said compound and said composition
BR112014000563A2 (en) compound, pharmaceutical composition, and compound use
AR056556A1 (en) IMIDAZO (1,2-A) PIRIDINE WITH CELLULAR ANTIPROLIFERATION ACTIVITY
AR060545A1 (en) COMPOUNDS OF BENZOAXOL AND BENZOTIAZOL 6-0- SUBSTITUTES AND INHIBITION METHODS OF SIGNALING OF CSF-1R. PHARMACEUTICAL COMPOSITIONS
AR072047A1 (en) USEFUL HETEROCICLICAL COMPOUNDS TO INHIBIT THE GIRASA DNA
AR046779A1 (en) DERIVATIVES OF PIRAZOL, METHODS FOR THEIR PREPARATION AND USES OF THE SAME IN THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS AND MEDICINES CONTAINING THEM WITH TRK INHIBITORY ACTIVITY FOR THE TREATMENT OR PROFILAXIS OF CANCER.
AR082391A1 (en) BICYCLE INHIBITORS OF ACETIL-COA AND USES OF THE SAME
AR091400A2 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES SULFAMIDE DERIVATIVES, PROCESS TO PREPARE IT AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES
AR074543A1 (en) IMIDAZO DERIVATIVES [1,2-A] PIRIDIN-2-IL, 1-PHYPHOSINE RECEPTOR AGONISTS (1S1P1), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD FOR PREPARING THEM AND USE OF THE SAME IN THE TREATMENT OF SELF DISEASES
AR083070A1 (en) ANALOGS OF NUCLEOTID REPLACED WITH NITROGEN HETEROCICLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT VIRAL DISEASES, IN PARTICULAR HCV INFECTIONS
UY30107A1 (en) NEW PIRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
AR062503A1 (en) PIRIDO DERIVATIVES [2, 3-D] PIRIMIDINE AND PIRAZIN [2, 3-D] PIRIMIDINE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATION BY THE INHIBITION OF MOTOR.
AR062526A1 (en) DERIVATIVES OF 4- (3-METHYLMORFOLIN-4-IL) PYRIMIDINE AND MORFOLIN-4-IL-PYRIMIDINE AS INHIBITORS OF MTOR QUINASA AND PI3K, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND THE USE OF THEM IN THE MANUFACTURE OF DRUGS FOR MEDICATION OF DIFFERENT TYPES OF CANCER.
AR053364A1 (en) COMPOSITE OF 1H-IMIDAZO 84,5-C) PIRIDIN -2- ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCESS TO PREPARE IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR TREATMENT OF CANCER OR ARTHRITIS
AR057380A1 (en) CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE AND THERAPEUTIC USE OF THE SAME
AR063643A1 (en) CHEMICAL COMPOUNDS DERIVED FROM QUINOLINA, A METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS
BRPI0707491B8 (en) compounds useful as mineralocorticoid receptor modulating agents, said agents comprising the same and pharmaceutical compositions
AR066020A1 (en) DERIVATIVES OF IMIDAZOLIDIN-2, 4-DIONA, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF PARP-1.
AR044116A1 (en) COMPOUNDS DERIVED FROM 5,7 DIAMINO PIRAZOLO [4,3-D] PYRIMIDINES, INTERMEDIARIES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE FOR THE MANUFACTURE OF MEDICATIONS
AR084553A1 (en) HIDEROCICLIC INHIBITING IMIDAZOLIC DERIVATIVES OF b-SECRETASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER
AR072045A1 (en) UREA HETEROCICLIC DERIVATIVES AND METHODS TO USE THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure